Interleukin (IL)-6 and receptor activator of nuclear factor (NF)-κB ligand (RANKL) are increased in the serum of a patient with primary pachydermoperiostosis

Scandinavian Journal of Rheumatology

Volumn 37, Issue 3, 2008, Pages 225-229

  Rendina, D ^a   De Filippo, G ^b,c   Viceconti, R ^a   Soscia, E ^a   Sirignano, C ^a   Salvatore, M ^a   Della Monica, M ^b   Scarano, G ^b   Mossetti, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UO Patologia Clinica AORN gRummo   (Italy)

^c G RUMMO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLCHICINE; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; TECHNETIUM 99M; TNFSF11 PROTEIN, HUMAN;

ADULT; ANAMNESIS; ARTICLE; BONE SCINTISCANNING; BONE TURNOVER; CAPILLAROSCOPY; CASE REPORT; CLINICAL FEATURE; HORMONE BLOOD LEVEL; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHROPATHY; OSTEOLYSIS; PHYSICAL EXAMINATION; PRIMARY PACHYDERMOPERIOSTOSIS; PRIORITY JOURNAL; ADOLESCENT; BLOOD; RADIOGRAPHY; SCINTISCANNING;

ADOLESCENT; HUMANS; INTERLEUKIN-6; MALE; OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC; RANK LIGAND;

EID: 45549109228     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701772457     Document Type: Article

References (24)

1. Castori M, Sinibaldi L, Mingarelli R, Lachman RS, Rimoin DL, Dallapiccola B. Pachydermoperiostosis: an update. Clin Gen 2005;68:477-86.
2. Auger M, Stavrianeas N, Pachydermoperiostosis. Orphanet encyclopedia, 2004. Available from: www.orpha.net (accessed December 2006).
3. White MP. Hereditary metabolic and dysplastic skeletal disorders. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2002:937-85.
4. Jajic Z, Jajic I, Nemcic T. Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res 2001;32:136-42.
5. Jajic I, Jajic Z, Grazio S. Minor but important symptoms and signs in primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 2001;19:357-8.
6. Hughes HE, McAlpine PJ, Cox DW, Philipps S. An autosomal dominant syndrome with 'acromegaloid' features and thickened oral mucosa. J Med Genet 1985;22:119-25.
7. Pichler G, Eber E, Thalhammer G, Muntean W, Zach MS. Arthralgia and digital clubbing in a child: hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung. Scand J Rheumatol 2004;33:189-91.
8. Oikarinen A, Palatsi R, Kylmaniemi M, Keski-Oja J, Risteli J, Kallioinen M. Pachydermoperiostosis: analysis of the connective tissue abnormality in one family. J Am Acad Dermatol 1994;31:947-53.
9. Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 1996;15:435-9.
10. Silveira LH, Martinez-Lavin M, Pineda C, Fonseca MC, Navarro C, Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000;18:57-62.
11. Matucci-Cerinic M, Martinez-Lavin M, Rojo F, Fonseca C, Kahaleh BM. von Willebrand factor antigen in hypertrophic osteoarthropathy. J Rheumatol 1992;19:765-7.
12. Fam AG, Chin-Sang H, Ramsay CA. Pachydermoperiostosis: scintigraphic, thermographic, plethysmographic, and capillaroscopic observations. Ann Rheum Dis 1983;42:98-102.
13. Matucci-Cerinic M, Fattorini L, Gerini G, Lombardi A, Pignone A, Petrini N, et al. Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis. Rheumatol Int 1988;8:185-8.
14. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002;1592:323-34.
15. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-7.
16. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
17. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005;37:601-6.
18. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002;1592:251-63.
19. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.
20. Mossetti G, Rendina D, De Filippo G, Viceconti R, Di Domenico G, Cioffi M, et al. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 2005;36:549-54.
21. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007;13:2825-30.
22. Knudsen LS, Ostergaard M, Baslund B, Narvestad E, Petersen J, Nielsen HJ, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol 2006;35:489-91.
23. Brandi ML, Collin-Osdoby P. Vascular biology and the skeleton. J Bone Miner Res 2006;21:183-92.
24. Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplant 2007;4:1139-46.